Trial Outcomes & Findings for Role of Contrast Enhanced Spectral Mammography to Predict Upgrade Rates of Biopsy Proven Atypical Ductal Hyperplasia (NCT NCT03505372)

NCT ID: NCT03505372

Last Updated: 2020-02-11

Results Overview

Investigators will evaluate whether enhancement on CESM can predict which cases of ADH upgrade at the time of surgical excision.

Recruitment status

TERMINATED

Study phase

NA

Target enrollment

5 participants

Primary outcome timeframe

3 months

Results posted on

2020-02-11

Participant Flow

5 patients were recruited

Participant milestones

Participant milestones
Measure
Contrast Enhanced Mammography
* The CESM images will be performed according to clinical protocol * Images will be acquired within approximately 2-12 minutes of contrast injection * A total of four images per breast will be acquired with low and high energy * Two radiologists will prospectively review the CESM, and will use a third as tie-breaker * The CESM will be evaluated for the biopsy site and up to two additional findings in either breast * The biopsy site will be evaluated for abnormal findings that would suggest malignant involvement Contrast enhanced mammography: Contrast enhanced mammography is a new type of mammogram that uses contrast material combined with the mammogram to highlight areas that might be breast cancer and that could be missed on the mammogram alone.
Overall Study
STARTED
5
Overall Study
COMPLETED
5
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Contrast Enhanced Mammography
n=5 Participants
* The CESM images will be performed according to clinical protocol * Images will be acquired within approximately 2-12 minutes of contrast injection * A total of four images per breast will be acquired with low and high energy * Two radiologists will prospectively review the CESM, and will use a third as tie-breaker * The CESM will be evaluated for the biopsy site and up to two additional findings in either breast * The biopsy site will be evaluated for abnormal findings that would suggest malignant involvement Contrast enhanced mammography: Contrast enhanced mammography is a new type of mammogram that uses contrast material combined with the mammogram to highlight areas that might be breast cancer and that could be missed on the mammogram alone.
Age, Categorical
<=18 years
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
5 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
Age, Continuous
50.2 years
n=5 Participants
Sex: Female, Male
Female
5 Participants
n=5 Participants
Sex: Female, Male
Male
0 Participants
n=5 Participants
Region of Enrollment
United States
5 Participants
n=5 Participants

PRIMARY outcome

Timeframe: 3 months

Population: Images were performed but outcome data was not collected and therefore we cannot provide any analysis.

Investigators will evaluate whether enhancement on CESM can predict which cases of ADH upgrade at the time of surgical excision.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 3 months

Population: Images were performed but outcome data was not collected and therefore we cannot provide any analysis.

Investigators will evaluate how incidental findings seen on CESM impact the surgical management of patients diagnosed with ADH. The initial surgical management documented in the clinical report (created before CESM performed) will be compared with the surgical management documented in the medical record after the CESM was performed to determine the change.

Outcome measures

Outcome data not reported

Adverse Events

Contrast Enhanced Mammography

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr Jordana Phillips

Beth Israel Deaconess Medical Center

Phone: 617 667 1630

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place